Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 13218

1.

Tumor necrosis factor-alpha inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: a multicenter retrospective study.

Rousset L, de Masson A, Begon E, Villani A, Battistella M, Rybojad M, Jachiet M, Bagot M, Bouaziz JD, Lepelletier C.

J Am Acad Dermatol. 2018 Oct 17. pii: S0190-9622(18)32735-X. doi: 10.1016/j.jaad.2018.10.006. [Epub ahead of print] No abstract available.

PMID:
30342166
2.

Efficacy and safety of Etanercept for postoperative Pyoderma Gangrenosum after infliximab serum sickness.

Ariane M, Bouaziz JD, de Masson A, Jachiet M, Bagot M, Lepelletier C.

Dermatol Ther. 2018 Oct 20:e12774. doi: 10.1111/dth.12774. [Epub ahead of print]

PMID:
30341800
3.

Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.

Scavone C, Sessa M, Clementi E, Corrao G, Leone R, Mugelli A, Rossi F, Spina E, Capuano A.

BioDrugs. 2018 Oct 20. doi: 10.1007/s40259-018-0313-2. [Epub ahead of print]

PMID:
30341487
4.

The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study.

Langford T, Arkir Z, Chalkidou A, Goddard K, Kaftantzi L, Samaan M, Irving P.

JMIR Res Protoc. 2018 Oct 19;7(10):e11218. doi: 10.2196/11218.

5.

Wide Variation in the Use and Understanding of Therapeutic Drug Monitoring for Anti-TNF Agents in Inflammatory Bowel Disease: An Inexact Science?

Samaan MA, Arkir Z, Ahmad T, Irving PM.

Expert Opin Biol Ther. 2018 Oct 19. doi: 10.1080/14712598.2018.1537367. [Epub ahead of print]

PMID:
30339466
6.

Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.

Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, Shimizu M, Akikawa K, Tanimura K, Atsumi T, Koike T.

Int J Rheum Dis. 2018 Oct 18. doi: 10.1111/1756-185X.13401. [Epub ahead of print]

PMID:
30338649
7.

Interventions for reducing inflammation in familial Mediterranean fever.

Wu B, Xu T, Li Y, Yin X.

Cochrane Database Syst Rev. 2018 Oct 19;10:CD010893. doi: 10.1002/14651858.CD010893.pub3. [Epub ahead of print] Review.

PMID:
30338514
8.

Serum free amino acid levels in rheumatoid arthritis according to therapy and physical disability.

Urbaniak B, Plewa S, Klupczynska A, Sikorska D, Samborski W, Kokot ZJ.

Cytokine. 2018 Oct 15. pii: S1043-4666(18)30390-9. doi: 10.1016/j.cyto.2018.10.002. [Epub ahead of print]

PMID:
30337216
10.

Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.

Ma D, Wong W, Aviado J, Rodriguez C, Wu H.

Am J Gastroenterol. 2018 Oct 17. doi: 10.1038/s41395-018-0368-1. [Epub ahead of print]

PMID:
30333541
11.

Trick or TREAT? More Safety Data of Infliximab During Pregnancy.

Kane S.

Am J Gastroenterol. 2018 Oct 17. doi: 10.1038/s41395-018-0372-5. [Epub ahead of print]

PMID:
30333536
12.

[Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody].

Song M, Li F, Xie X, Chen J, Tang M, Tian J, Du J, Ge Y, Li S, Xu S.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Sep 28;43(9):982-986. doi: 10.11817/j.issn.1672-7347.2018.09.008. Chinese.

13.

Cyclosporine for Moderate to Severe Plaque Psoriasis in Adults: A Review of Clinical Effectiveness and Safety [Internet].

Singh K, Argáez C.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Apr 3.

14.

Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.

Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-Biroulet L.

Inflamm Bowel Dis. 2018 Oct 16. doi: 10.1093/ibd/izy322. [Epub ahead of print]

PMID:
30329067
15.

Successful treatment of psoriatic arthritis associated with adrenal hypoplasia congenita using infliximab.

Kimura K, Fujimoto A, Deguchi T, Ansai O, Tsuchida Y, Hama N, Kondo N, Nagasaki K, Ishida W, Abe R.

Eur J Dermatol. 2018 Oct 15. doi: 10.1684/ejd.2018.3382. [Epub ahead of print] No abstract available.

PMID:
30325329
16.

A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.

Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I.

Biologics. 2018 Oct 2;12:97-106. doi: 10.2147/BTT.S172241. eCollection 2018.

17.

Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it!

van Langenberg DR, Vasudevan A.

Aliment Pharmacol Ther. 2018 Nov;48(9):1028-1029. doi: 10.1111/apt.14959. No abstract available.

18.

Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?

Orfanoudaki E, Drygiannakis I, Koutroubakis IE.

Aliment Pharmacol Ther. 2018 Nov;48(9):1037-1038. doi: 10.1111/apt.14980. No abstract available.

19.

Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply.

Dreesen E, Gils A.

Aliment Pharmacol Ther. 2018 Nov;48(9):1029-1030. doi: 10.1111/apt.14974. No abstract available.

20.

Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study.

Alperi-López M, Alonso-Castro S, Morante-Bolado I, Queiro-Silva R, Riestra-Noriega JL, Arboleya L, Ballina-García FJ.

Reumatol Clin. 2018 Oct 11. pii: S1699-258X(18)30182-7. doi: 10.1016/j.reuma.2018.08.002. [Epub ahead of print] English, Spanish.

Supplemental Content

Loading ...
Support Center